Skip to main content

Table 2 Mean change in WOMAC A1 from baseline over 26 weeks

From: Efficacy and safety of a single intra-articular injection of 6 ml Hylan G-F 20 compared to placebo in Chinese patients with symptomatic knee osteoarthritis

  Placebo (N = 220) Single 6 ml Hylan G-F 20 injection (N = 218)
Baseline
 Number 220 216
 Mean (SD) 5.2 (1.3) 5.3 (1.2)
 Median 5.0 5.0
 Min; Max 0; 8 1; 8
Change from baseline over 26 weeks
 LS Mean (SE) −2.271 (0.110) −2.146 (0.108)
 LS Mean Difference (SE) vs. Placebo   0.125 (0.137)
 95% CI   (−0.144 to 0.395)
P-value   0.3610
  1. Least-square (LS) means, standard errors (SE) and p-value are taken from repeated measures of Covariance analysis. The model includes treatment groups (Single 6 ml Hylan G-F 20 injection and placebo), site, visit and visit by treatment interaction, as well as the baseline WOMAC A1 score as a covariate. Included are patients who have measurements at baseline and at least one post-baseline value